Rapid Micro Biosystems, Inc.
NASDAQ:RPIDMedical - Devices
+$0.03 today
- Market cap
- $50.31M
- Beta
- 1.46
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.10
Volume 0.17M
Average 0.18M
RPID Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Rapid Micro Biosystems, Inc.NASDAQ: RPID
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $15.45M (cash outflow) rose 64.7% year over year, ahead of the -4.4% change in trailing-twelve-month free cash flow. Sequentially, it rose 528.1% from the prior quarter. Over 3 fiscal years it compounded at -21.2% a year.
Context
- Free cash flow amounted to 95.0% of revenue in FY2025, down 67.3 pp from a year earlier.
- Free cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +64.7% holds above the trailing-twelve-month pace of -4.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (31.91M) USD
- Year-over-year change
- +29.9%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (31.91M) | +29.9% |
| FY2024 | 2024-12-31 | (45.52M) | +3.0% |
| FY2023 | 2023-12-31 | (46.93M) | +28.1% |
| FY2022 | 2022-12-31 | (65.29M) | -12.2% |
| FY2021 | 2021-12-31 | (58.18M) | — |
Free Cash Flow vs competitors
How RPID compares with its peers on the latest reported figures
- RPID's LTM Mar 2026 free cash flow of $37.1M is the 2nd largest of the 9 companies compared; the peer median is $23.39M.
- Its year-over-year change of -4.4% is the 5th highest of 9, against a peer median of -11.0%.
- Free cash flow amounts to 107.9% of revenue for RPID, versus a peer median of 31.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $46.44M | +3.9% | +15.0% | 904.6% | |
| LTM Mar 2026 | $37.1M | -4.4% | -21.2% | 107.9% | |
| LTM Mar 2026 | $30.75M | -34.2% | +18.9% | 42.5% | |
| LTM Mar 2026 | $27.58M | +1.6% | -9.4% | 48377.2% | |
| LTM Mar 2026 | $26.52M | +21.6% | +10.1% | — | |
| LTM Mar 2026 | $20.25M | -34.9% | +9.5% | — | |
| LTM Mar 2026 | $12.24M | +202.4% | -0.1% | 21.2% | |
| LTM Mar 2026 | $11.16M | -23.6% | -48.9% | 10.4% | |
| LTM Mar 2026 | $8.99M | -31.6% | -24.6% | 16.1% | |
| Peer median (excluding RPID) | $23.39M | -11.0% | +4.7% | 31.9% | |
Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.52M) | (60.81M) | (52.47M) | (46.89M) | (47.12M) |
| Depreciation & Amortization | 1.53M | 2.84M | 3.11M | 3.36M | 3.25M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.84M | 4.02M | 4.75M | 3.87M | 4.03M |
| Change in Working Capital | (8M) | (5.33M) | 555K | (4.77M) | 6.06M |
| Accounts Receivables | (17K) | (364K) | (163K) | (1.99M) | 4.39M |
| Inventory | (6.77M) | (5.84M) | 1.19M | (335K) | 1.47M |
| Accounts Payables | (524K) | 1.48M | (3.46M) | 562K | 1.6M |
| Other Working Capital | (691K) | (602K) | 2.98M | (3.01M) | (1.39M) |
| Other Non-Cash Items | 23.19M | 728K | (1.02M) | 271K | 2.71M |
| Operating Cash Flow | (54.96M) | (58.55M) | (45.08M) | (44.15M) | (31.06M) |
| Capital Expenditures | (3.22M) | (6.74M) | (1.85M) | (1.37M) | (850K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (25.09M) | (179.23M) | (62.49M) | (35.04M) | (27.08M) |
| Sales of Investments | 15M | 92.5M | 106.49M | 73.06M | 42.26M |
| Other Investing Activities | 20K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (13.29M) | (93.47M) | 42.15M | 36.66M | 14.33M |
| Debt Repayment | (26.17M) | (33K) | (37K) | (35K) | 19.09M |
| Common Stock Issued | 164.11M | 0 | 0 | 238K | 1.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (940K) | 726K | 186K | 0 | (419K) |
| Financing Cash Flow | 216.75M | 693K | 149K | 203K | 19.77M |
| Effect of Forex Changes | 0 | 0 | 0 | (81K) | 0 |
| Net Change in Cash | 148.49M | (151.32M) | (2.78M) | (7.37M) | 3.04M |
| Free Cash Flow | (58.18M) | (65.29M) | (46.93M) | (45.52M) | (31.91M) |
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.